{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"Disease free survival - measured by (absence of ) relapse/recurrence or death.\n\nRelapse and recurrence, both will be measured by greater than 5% circulating leukemic blasts in the marrow or peripheral blood and/or the presence of blasts in any extra medullary site and/or disease determined by clinical assessment.","groups":[{"description":"5 x 10\\^5/kg at 6-7 weeks post-transplant (Group A), 4-5 weeks post-transplant (Group B), or 2-3 weeks post-transplant (Group C)\n\nT-cell Receptor α/β Depleted Donor Lymphocyte Infusions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients","id":"OG000","title":"HLA Matched Cohort I"},{"description":"5 x 10\\^5/kg starting time point X (whichever was safest as determined by Matched Cohort I), 1 x 10\\^6/kg 3-4 weeks after first dose, and 1 x 10\\^6/kg 3-4 weeks after second dose\n\nT-cell Receptor α/β Depleted Donor Lymphocyte Infusions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients","id":"OG001","title":"HLA Matched Cohort II"},{"description":"5 x 10\\^5/kg starting time point X (whichever was safest as determined by Matched Cohort I), 1 x 10\\^6/kg 3-4 weeks after first dose, and 2 x 10\\^6/kg 3-4 weeks after second dose\n\nT-cell Receptor α/β Depleted Donor Lymphocyte Infusions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients","id":"OG002","title":"HLA Matched Cohort III"},{"description":"1 x 10\\^5/kg at 6-7 weeks post-transplant (Group A), 4-5 weeks post-transplant (Group B), or 2-3 weeks post-transplant (Group C)\n\nT-cell Receptor α/β Depleted Donor Lymphocyte Infusions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients","id":"OG003","title":"HLA Mismatched Cohort I"},{"description":"1 x 10\\^5/kg starting time point Y (whichever was safest as determined by Mismatched Cohort I), 5 x 10\\^5/kg 3-4 weeks after first dose, and 5 x 10\\^5/kg 3-4 weeks after second dose\n\nT-cell Receptor α/β Depleted Donor Lymphocyte Infusions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients","id":"OG004","title":"HLA Mismatched Cohort II"},{"description":"1 x 10\\^5/kg starting time point Y (whichever was safest as determined by Mismatched Cohort I), 5 x 10\\^5/kg 3-4 weeks after first dose, and 1 x 10\\^6/kg 3-4 weeks after second dose\n\nT-cell Receptor α/β Depleted Donor Lymphocyte Infusions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients","id":"OG005","title":"HLA Mismatched Cohort III"}],"populationDescription":"Because the study was terminated early, no participants completed 2 years.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Disease Free Survival- Measured by Absence of Relapse/Recurrence or Death.","type":"SECONDARY"}